Defective Breast Mesh, Acellular Dermal Matrix, and Bioabsorbable Scaffold Injury Attorneys in Delaware: The Definitive Guide for Women, Families, and Survivors
For women in Delaware who have undergone breast reconstruction, revision, or cosmetic augmentation, the expectation is always one of healing, restoration, and a return to a life of confidence. Whether you were treated at a major health system like ChristianaCare’s Helen F. Graham Cancer Center & Research Institute in Newark, or a specialized surgical center in Wilmington, Dover, or Lewes, you placed your trust in the medical devices implanted within your body. However, across the First State and the nation, a growing number of women are discovering that the surgical meshes, acellular dermal matrices (ADM), and bioabsorbable scaffolds used in their procedures — often without their knowledge of the risks — are failing with catastrophic results.
We understand the physical and emotional toll these complications take. We know that for a breast cancer survivor, a reconstruction failure is not just a medical setback; it is a disruption of the survivorship journey. We recognize that for a cosmetic patient, a disfiguring injury can lead to a lifetime of revision surgeries and psychological distress. At The Manginello Law Firm, PLLC, operating as Attorney911, we have dedicated our practice to protecting victims of institutional and corporate negligence. Led by Managing Partner Ralph P. Manginello, who has been licensed to practice for twenty-seven continuous years (State Bar of Texas Bar Card Number 24007597), and Associate Attorney Lupe Eleno Peña (State Bar of Texas Bar Card Number 24084332), our team brings an aggressive, technical, and bilingual approach to medical device litigation.
If you are suffering from redness, swelling, infection, or a diagnosis of BIA-ALCL or BIA-SCC after your surgery in Delaware, you deserve answers rooted in federal law, medical science, and a deep understanding of how device manufacturers failed to warn the public. This guide is designed to provide those answers, helping you navigate the complex world of FDA regulations, product liability, and the path to recovery.
Understanding the Devices: Mesh, ADM, and Scaffolds
In the world of Delaware breast surgery, surgeons often use “internal bra” techniques to provide support for implants or tissue. To do this, they use three primary categories of materials, each carrying distinct risks:
- Acellular Dermal Matrix (ADM): These are biological tissues, typically derived from human cadavers or porcine (pig) skin, that have been processed to remove all cells while leaving the structural collagen matrix intact. Common brands used in Delaware include AlloDerm (Allergan/AbbVie), Strattice (Allergan/AbbVie), FlexHD (MTF Biologics), and AlloMax (Becton Dickinson).
- Bioabsorbable Scaffolds: These are synthetic materials designed to provide temporary support while the body builds its own tissue, eventually dissolving or “resorbing.” The most prominent examples are made from poly-4-hydroxybutyrate (P4HB), such as GalaFLEX (Galatea Surgical/Becton Dickinson) and Phasix (C.R. Bard/Becton Dickinson).
- Synthetic Surgical Mesh: Often made of polypropylene, these are permanent meshes that have been used off-label in breast surgery, despite having been designed for hernia or pelvic repair.
It is critical for Delaware patients to know that the safety and effectiveness of surgical mesh in breast surgery, including in augmentation or reconstruction, has not been determined by the FDA. We are currently representing clients in high-stakes litigation, such as the Bermudez v. Pi Kappa Phi case (Harris County, TX), where we are seeking $10,000,000 in damages against major institutions. This same level of aggressive investigation is required when taking on multi-billion-dollar device manufacturers like Becton Dickinson (BD) or Allergan.
If you are concerned about a device used in your surgery, we invite you to contact us at 1-888-ATTY-911 for a confidential, no-obligation consultation. Our associate, Lupe Peña, is fluent in Spanish and conducts full client consultations in the language you speak at home, ensuring that no detail is lost in translation.
The FDA Regulatory Failure: 510(k) and “Predicate Creep”
Many women in Delaware are surprised to learn that the mesh or ADM in their bodies was never actually “approved” by the FDA for breast surgery. Instead, these devices typically reach the market via the 510(k) clearance pathway (21 USC §360c and 21 CFR Part 807 Subpart E).
Under the 510(k) pathway, a manufacturer does not have to prove a device is safe or effective through clinical trials. They only have to show it is “substantially equivalent” to a “predicate device” already on the market. This has led to a phenomenon known as “predicate creep.” For example, the manufacturer of GalaFLEX cited a surgical suture as its predicate device. By linking a mesh to a suture, and then a newer mesh to that older mesh, manufacturers have bypassed the rigorous Premarket Approval (PMA) pathway (21 CFR Part 814).
In Medtronic v. Lohr (518 U.S. 470, 1996), the Supreme Court established that 510(k) clearance does not preempt state-law claims. This means that even if a manufacturer like Becton Dickinson claims their mesh is “FDA-cleared,” they can still be held liable for design defects and failure to warn under Delaware’s product liability framework. We track these federal precedents closely to ensure our clients’ rights are protected against the defense’s attempts to use “federal preemption” as a shield.
Serious Complications: What Delaware Patients Must Watch For
Complications from these devices can range from “Red Breast Syndrome” to life-threatening malignancies. If you were treated at a Delaware facility such as Bayhealth Medical Center or Beebe Healthcare, you must be vigilant in monitoring for the following:
BIA-ALCL: Breast Implant-Associated Anaplastic Large Cell Lymphoma
This is a CD30-positive, ALK-negative T-cell lymphoma that develops in the scar tissue (capsule) around the implant. It is most strongly associated with textured surfaces, such as those found in the Allergan BIOCELL textured implants recalled in July 2019. The world of medical science recognized this as a distinct lymphoma in 2016, yet many patients were not warned for years.
BIA-SCC: Breast Implant-Associated Squamous Cell Carcinoma
A rarer but aggressive epithelial tumor identified in the implant capsule. The FDA issued an updated safety communication regarding BIA-SCC on March 8, 2023, noting that symptoms can present decades after the initial surgery.
Red Breast Syndrome
Specifically associated with ADM, this is a non-infectious, sterile inflammation. Research suggests it is mediated by endotoxins (bacterial fragments) that survive the sterilization process. If your breast remains bright red without a fever or high white blood cell count, it may be a reaction to the ADM (like FlexHD or AlloMax) rather than a standard infection.
Reconstruction Failure and Sepsis
When a bioabsorbable scaffold like GalaFLEX or Phasix fails to resorb as advertised, or when an ADM fails to integrate, it can lead to skin-flap necrosis, extrusion (the device pushing through the skin), and systemic sepsis. These outcomes often require multiple revision surgeries, removing all reconstruction and leaving the patient with a flat closure.
Our firm, led by Ralph Manginello, has decades of experience handling cases involving catastrophic infections and permanent disfigurement. We serve clients across Delaware, including the Newark, Wilmington, and Dover areas, ensuring that the heavy emotional weight of these cases is met with technical litigation expertise. Call us at 1-888-288-9911 if you are experiencing any of these symptoms.
The Whistleblower Evidence: Dr. Hooman Noorchashm
A critical piece of evidence in the fight against scaffold manufacturers like Becton Dickinson is the testimony of whistleblowers. Dr. Hooman Noorchashm, a cardiothoracic surgeon and former Medical Director at BD, was terminated in 2022 after raising serious safety concerns about the marketing of GalaFLEX.
Dr. Noorchashm has alleged that BD withheld data regarding breast cancer recurrences in its clinical trials and failed to accurately report adverse events to the FDA’s MAUDE (Manufacturer and User Facility Device Experience) database. These allegations strike at the heart of “failure to warn” claims. If a manufacturer knows of a risk and hides it from the FDA and surgeons, they have breached their duty to the women of Delaware.
Legal Rights and Statutes of Limitations in Delaware
In Delaware, the statute of limitations for personal injury and product liability is generally two years from the date the injury occurred or was discovered (10 Del. C. § 8119). However, because many device-related injuries are latent — such as BIA-ALCL which can take 7 to 10 years to develop — the “discovery rule” is vital. This rule may pause the clock until the moment you knew, or reasonably should have known, that the device caused your harm.
Delaware follows a modified comparative negligence rule. This means that as long as you are not more than 50% responsible for your injury, you can recover damages. Since these cases involve internal medical devices, the “fault” almost never lies with the patient, but rather with the manufacturer (design/manufacturing defect) or the surgeon (medical malpractice or failure to obtain informed consent).
Ralph Manginello and Lupe Peña are admitted to the U.S. District Court for the Southern District of Texas and have extensive experience in federal litigation. For Delaware residents, these cases are often heard in the United States District Court for the District of Delaware in Wilmington, a venue known for handling complex corporate and multidistrict litigation (MDL). We understand the realist path through the federal docket and are prepared to prosecute cases against global corporations.
How to Discover Which Device Was Used in Your Surgery
Many patients do not know the brand of mesh or matrix used in their reconstruction. To find out, you must take these steps:
- Request your Operative Report: This is the detailed narrative your surgeon wrote after the procedure.
- Look for Device Implant Stickers: These stickers contain the Brand Name, Lot Number, and Unique Device Identifier (UDI). Hospitals are required to keep these in your chart.
- Check your Patient Portal: Systems like ChristianaCare or Bayhealth often have “Implanted Devices” sections in their digital portals.
If you are having trouble getting this information, we can help. At Attorney911, we are investigators as much as we are litigators. We know how to sleuth through medical records to find the lot numbers that tie your injury to a specific manufacturer.
Why Choose Attorney911 for Your Delaware Case?
Choosing a lawyer is a significant decision, especially when your health is on the line. Generalist personal injury firms may not understand the specific pathology of CD30+ ALK- lymphoma or the hydrolysis kinetics of P4HB scaffolds. We distinguish ourselves through:
- Substantive Expertise: We don’t just “handle” cases; we understand the science. We cite 21 CFR §803 reporting requirements and Riegel-progeny case law because we have spent twenty-seven years in the trenches of the legal system.
- Active High-Profile Litigation: We are currently lead counsel in major multi-defendant lawsuits, proving we have the resources and the “firepower” to take on large institutions.
- Bilingual Representation: Lupe Peña ensures that our Spanish-speaking clients in Delaware have direct access to their attorney, not just an interpreter. Hablamos su idioma y luchamos por sus derechos.
- Proven Ratings: With an 8.2 Avvo Rating and Martindale-Hubbell Preeminent status, Ralph Manginello is recognized by his peers and clients alike for excellence in practice.
We work on a contingency fee basis, meaning there is no fee unless we recover compensation for you. We are members of the Pro Bono College of the State Bar of Texas, a testament to our commitment to service and justice.
Frequently Asked Questions for Delaware Patients
Is breast mesh actually approved by the FDA?
No. The FDA confirmed in its November 9, 2023, letter to health care providers that “the safety and effectiveness of surgical mesh in breast surgery… has not been determined by the FDA.” Most are “cleared” through the 510(k) pathway, which is a much lower standard than “approval.”
What is the “internal bra” procedure?
This typically refers to using a scaffold like GalaFLEX or an ADM like Strattice to support the lower part of the breast. While it can produce a good initial aesthetic result, the long-term risks include palpable mesh edges, chronic pain, and late-onset failure.
Can I sue if my surgery was five years ago?
Yes. Because injuries like BIA-ALCL and mesh degradation often take years to manifest, the personal injury clock in Delaware often doesn’t start until you discover the injury and its link to the device.
What is the status of the Allergan BIOCELL MDL?
The consolidated litigation (MDL 2921) is currently proceeding in the District of New Jersey. The first bellwether trial is scheduled for October 19, 2026. This trial will be a critical indicator of how juries value these cancer-related claims.
Who do we sue?
The primary defendant is usually the manufacturer (e.g., Becton Dickinson, Allergan, MTF Biologics). However, we also look at the roles of distributors and, in some cases, the surgical facility if there was a failure in credentialing or informed consent.
What damages can I recover?
You may be entitled to “economic damages” (the cost of all revision surgeries, lost wages, and future medical care) and “non-economic damages” (pain and suffering, emotional distress, and permanent disfigurement).
Contact a Delaware Defective Breast Device Attorney Today
If you or a loved one are suffering from the failure of a breast mesh, ADM, or scaffold, you are not alone. There is a community of survivors in Delaware and across the country who are standing up to these manufacturers. Whether you were treated in the ChristianaCare system or at a private aesthetic clinic, your rights are the same.
The path to justice starts with a single conversation. We are here to listen, to investigate, and to fight. Call Ralph Manginello and the team at Attorney911 today at 1-888-ATTY-911 (1-888-288-9911). You can also reach us through our digital platforms or by visiting us online.
Past results do not guarantee future outcomes. Every case is different. This content is for educational purposes and does not constitute legal advice. Contact us for a free consultation regarding your specific situation.
When you are ready to take the next step, our door is open. We represent the women of Delaware with the aggressive, technical, and compassionate advocacy they deserve.
Attorney911 | The Manginello Law Firm, PLLC
1-888-ATTY-911 (1-888-288-9911)
Hablamos Español. Su consulta es gratuita y confidencial.
